Papillomavirus genomes associate with BRD4 to replicate at fragile sites in the host genome

Moon Kyoo Jang1, Kui Shen2, Alison A McBride1

  • 1Laboratory of Viral Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, United States of America.

Plos Pathogens
|May 17, 2014
PubMed

Insights

Persistent E2 and BRD4-Broad Localized Enrichments of Chromatin (PEB-BLOCs) are genomic regions targeted by papillomavirus. These sites, prone to DNA damage, facilitate viral integration and HPV-associated cancers.

Area of Science:

  • Genomics
  • Virology
  • Cancer Biology

Background:

  • Oncogenic viruses frequently integrate near common fragile sites.
  • The papillomavirus E2 protein, with BRD4, anchors viral DNA to host chromatin for replication.

Purpose of the Study:

  • To map the genomic targets of papillomavirus E2 and BRD4 interaction.
  • To investigate the association between these targets and fragile sites in HPV infection.

Main Methods:

  • Genome-wide mapping of Persistent E2 and BRD4-Broad Localized Enrichments of Chromatin (PEB-BLOCs).
  • FANCD2 ChIP-chip in human C-33 cervical cells to map fragile sites.
  • Microscopy to visualize viral DNA replication foci in HPV-infected cells.

Main Results:

  • PEB-BLOCs were identified as large genomic regions frequently containing deletions and asynchronous replication.
  • PEB-BLOCs are strongly associated with common fragile sites.
  • HPV replication foci form adjacent to PEB-BLOCs, suggesting a link to fragile site susceptibility.

Conclusions:

  • Papillomavirus replication occurs near susceptible fragile sites (PEB-BLOCs).
  • This proximity increases the likelihood of viral integration at these sites.
  • The findings provide a mechanism for viral integration in HPV-associated cancers.

Related Concept Videos

Mitral Valve Prolapse III: Nursing Management01:19

Mitral Valve Prolapse III: Nursing Management

The nursing management of Mitral Valve Prolapse, or MVP, centers around patient education, symptom monitoring, and lifestyle modifications.Patient Education on MVP Diagnosis and Heredity: Nurses should provide comprehensive education about MVP, a condition where the mitral valve does not close appropriately during heartbeats. This education often includes the condition's pathophysiology, symptoms, and potential complications, like arrhythmias or mitral regurgitation. Though not fully...
252
Cancer Vaccines01:30

Cancer Vaccines

Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
917
Development of Immunocompetence01:22

Development of Immunocompetence

The initiation of cell-mediated immunity can be observed as early as the third month of fetal growth, with active antibody-mediated immunity following approximately one month later.
The initial cells that migrate from the fetal thymus settle within the skin and epithelial tissues lining the mouth, digestive tract, and in females, the uterus and vagina. These cells, including skin-based dendritic cells, serve as antigen-presenting cells, playing a key role in T cell activation.
Subsequent T...
759
Vaccinations01:51

Vaccinations

Overview
51.1K
Healthcare Associated Infections II: Preventive Measures01:22

Healthcare Associated Infections II: Preventive Measures

Essential infection prevention measures are based on the knowledge of the infection chain, the modes of transmission in healthcare settings, and the use of the best practices in all healthcare settings. Compulsory public reporting of healthcare-associated infection rates is needed to allow individuals and the community to make informed choices regarding selecting a healthcare facility.
The best practices for preventing healthcare-associated infections include hand hygiene, patient risk...
3.5K
Teratogenicity01:07

Teratogenicity

The ability of a drug to produce structural deformations and functional abnormalities in the developing embryo or the fetus is called teratogenicity, and the drug producing this effect is known as a teratogen. Teratogenic effects include stillbirth, miscarriage, intrauterine growth restriction, and neurocognitive delay. A teratogen may affect the embryo at different stages of development, which is important in determining the type and extent of the damage. During blastocyst formation, the early...
3.9K